AGP Executive Report
Last update: 10 hours agoHepatitis B Trial: A controversial study in Guinea-Bissau has received approval from the University of Southern Denmark and local officials, according to reports. Researchers plan to enroll 14,000 newborns, giving half the hepatitis B vaccine at birth and delaying it for the others for six weeks. Critics say withholding a proven, protective dose exposes babies to preventable risk; nearly one in five people in Guinea-Bissau are infected with hepatitis B. The trial was previously paused, and reports say the CDC is preparing $1.6 million in funding, though it is unclear whether the study will now proceed.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
